血浆成纤维细胞生长因子21与非酒精性脂肪性肝炎严重程度相关
横断面研究纳入187例BMI>25患者,评估血浆FGF21与肝活检证实的非酒精性脂肪性肝炎(NASH)严重程度的关系。血浆FGF21在NASH组(453±262 pg/mL)高于无NASH组(341±198 pg/mL)和无NAFLD组(325±289 pg/mL),且随坏死性炎症和纤维化严重程度增加,但与脂肪变性程度无关。FGF21与脂肪组织和骨骼肌胰岛素敏感性呈负相关。
要点
- NASH患者血浆FGF21水平显著高于无NASH和无NAFLD者。
- 血浆FGF21随坏死性炎症和纤维化严重程度增加,但与脂肪变性无关。
- FGF21与脂肪组织和骨骼肌胰岛素敏感性呈负相关,与肝脏胰岛素敏感性无关。
核心结论
- 血浆FGF21与NASH患者脂肪性肝炎严重程度相关,尤其是纤维化。
- 测量FGF21可能有助于识别疾病进展风险最高的患者。
研究设计与样本
- 横断面研究,在大学医院进行,纳入187例BMI>25的患者。
- 所有患者接受高胰岛素-正葡萄糖钳夹评估组织特异性胰岛素抵抗,肝脏磁共振波谱定量肝内甘油三酯,空腹血浆FGF21检测;146例存在NAFLD者接受肝活检。
主要发现
- NASH组(n=94)血浆FGF21为453±262 pg/mL,高于无NASH组(n=52;341±198 pg/mL,P=0.03)和无NAFLD组(n=41;325±289 pg/mL,P=0.02)。
- 血浆FGF21与脂肪组织胰岛素敏感性呈负相关(r=-0.17,P=0.006),与骨骼肌胰岛素敏感性呈负相关(r=-0.23,P=0.007),与肝脏胰岛素敏感性无相关性。
- 血浆FGF21随坏死性炎症严重程度增加(P=0.02),随纤维化严重程度增加更显著(P<0.001),但与脂肪变性加重无关(P=0.60)。
临床怎么用
- 在肥胖和2型糖尿病患者中,血浆FGF21水平可能辅助识别NASH及纤维化风险较高的个体。
局限性
- 横断面设计无法确定因果关系。
- 样本来自单一大学医院,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The relationship between plasma fibroblast growth factor 21 (FGF21), insulin resistance, and steatohepatitis has not been systematically assessed. OBJECTIVE: To determine if higher plasma FGF21 is associated with worse steatohepatitis on liver biopsy in patients with nonalcoholic fatty liver disease (NAFLD). DESIGN AND SETTING: Cross-sectional study in a university hospital. PATIENTS INTERVENTIONS AND MAIN OUTCOME MEASURES: Patients with a body mass index >25 (n = 187) underwent: (i) euglycemic hyperinsulinemic clamp to assess tissue-specific insulin resistance (IR); (ii) liver magnetic resonance spectroscopy for intrahepatic triglyceride quantification, (iii) liver biopsy (if NAFLD present; n = 146); and (iv) fasting plasma FGF21 levels. METHODS AND RESULTS: Patients were divided into three groups: (i) No NAFLD (n = 41); (ii) No nonalcoholic steatohepatitis (NASH) (patients with isolated steatosis or borderline NASH; n = 52); and (iii) NASH (patients with definite NASH; n = 94). Groups were well-matched for age/sex, prevalence of type 2 diabetes mellitus, and hemoglobin A1c. During euglycemic hyperinsulinemic insulin clamp, insulin sensitivity in skeletal muscle and adipose tissue worsened from No NAFLD to NASH (both P < 0.001). Plasma FGF21 levels correlated inversely with insulin sensitivity in adipose tissue (r = -0.17, P = 0.006) and skeletal muscle (r = -0.23, P = 0.007), but not with liver insulin sensitivity. Plasma FGF21 was higher in patients with NASH (453 ± 262 pg/mL) when compared with the No NASH (341 ± 198 pg/mL, P = 0.03) or No NAFLD (325 ± 289 pg/mL, P = 0.02) groups. Plasma FGF21 increased with the severity of necroinflammation (P = 0.02), and most significantly with worse fibrosis (P < 0.001), but not with worsening steatosis (P = 0.60). CONCLUSIONS: Plasma FGF21 correlates with severity of steatohepatitis, in particular of fibrosis, in patients with NASH. Measurement of FGF21 may help identify patients at the highest risk of disease progression.
引用
- Barb D, Bril F, Kalavalapalli S, et al. Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes. J Clin Endocrinol Metab. 2019. PMID: 30848827. doi:10.1210/jc.2018-02414
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。